Cargando…

Natalizumab Treatment for Relapsing Multiple Sclerosis Stabilises Normal-Appearing White Matter Microstructure: A One-Year Prospective Ultra-High-Field Quantitative Imaging Study

(1) Background: Natalizumab dramatically reduces relapses and MRI inflammatory activity (new lesions and enhancing lesions) in multiple sclerosis (MS). Chemical exchange saturation transfer (CEST) MRI can explore brain tissue in vivo with high resolution and sensitivity. We investigated if natalizum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanasescu, Radu, Mougin, Olivier, Chou, I-Jun, Al-Radaideh, Ali, Jerca, Oltita P., Lim, Su-Yin, Gowland, Penny, Constantinescu, Cris S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605806/ https://www.ncbi.nlm.nih.gov/pubmed/37891832 http://dx.doi.org/10.3390/brainsci13101464

Ejemplares similares

Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells
por: Tanasescu, Radu, et al.
Publicado: (2023)

Reduced Myelin Signal in Normal-appearing White Matter in Neuromyelitis Optica Measured by 7T Magnetic Resonance Imaging
por: Chou, I-Jun, et al.
Publicado: (2019)

Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2017)

T167. ABERRANT MYELINATION OF THE CINGULUM BUNDLE IN PATIENTS WITH SCHIZOPHRENIA: A 7T MTI/DTI STUDY
por: Palaniyappan, Lena, et al.
Publicado: (2018)

A comparison of phase imaging and quantitative susceptibility mapping in the imaging of multiple sclerosis lesions at ultrahigh field
por: Cronin, Matthew John, et al.
Publicado: (2016)

Role of oral teriflunomide in the management of multiple sclerosis
por: Tanasescu, Radu, et al.
Publicado: (2013)

An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis
por: Dumitrescu, Laura, et al.
Publicado: (2023)

Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis
por: Aram, Jehan, et al.
Publicado: (2018)

CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS
por: Astbury, Lauren, et al.
Publicado: (2022)

Localised Grey Matter Atrophy in Multiple Sclerosis and Clinically Isolated Syndrome—A Coordinate-Based Meta-Analysis, Meta-Analysis of Networks, and Meta-Regression of Voxel-Based Morphometry Studies
por: Singh, Sonika, et al.
Publicado: (2020)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Structural correlates of formal thought disorder in schizophrenia: An ultra-high field multivariate morphometry study
por: Palaniyappan, Lena, et al.
Publicado: (2015)

Experimental infection with the hookworm, Necator americanus, is associated with stable gut microbial diversity in human volunteers with relapsing multiple sclerosis
por: Jenkins, Timothy P., et al.
Publicado: (2021)

Coordinate Based Meta-Analysis of Functional Neuroimaging Data; False Discovery Control and Diagnostics
por: Tench, Christopher R., et al.
Publicado: (2013)

Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis
por: Mellergård, Johan, et al.
Publicado: (2012)

Diffusion Tensor Imaging Revealed Microstructural Changes in Normal-Appearing White Matter Regions in Relapsing–Remitting Multiple Sclerosis
por: Bao, Jianfeng, et al.
Publicado: (2022)

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Coordinate Based Meta-Analysis of Functional Neuroimaging Data Using Activation Likelihood Estimation; Full Width Half Max and Group Comparisons
por: Tench, Christopher R., et al.
Publicado: (2014)

An Absence of Epstein–Barr Virus Reactivation and Associations with Disease Activity in People with Multiple Sclerosis Undergoing Therapeutic Hookworm Vaccination
por: Maple, Peter A. C., et al.
Publicado: (2020)

Is Human Auditory Cortex Organization Compatible With the Monkey Model? Contrary Evidence From Ultra-High-Field Functional and Structural MRI
por: Besle, Julien, et al.
Publicado: (2019)

T166. SPATIAL INCOHERENCE OF LARGE-SCALE CORTICAL NETWORKS RELATES TO FORMAL THOUGHT DISORDER IN SCHIZOPHRENIA: A 7T MRI-BASED THICKNESS STUDY
por: Palaniyappan, Lena, et al.
Publicado: (2018)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis
por: Morandi, Elena, et al.
Publicado: (2017)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
por: Alroughani, R., et al.
Publicado: (2013)

Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis
por: O'Leary, Shirley, et al.
Publicado: (2023)

Investigating Microstructural Changes in White Matter in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Neurite Orientation Dispersion and Density Imaging
por: Alotaibi, Abdulmajeed, et al.
Publicado: (2021)

Natalizumab treatment reduces microglial activation in the white matter of the MS brain
por: Sucksdorff, Marcus, et al.
Publicado: (2019)

Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort
por: Papeix, Caroline, et al.
Publicado: (2016)

Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report
por: Lee, De-Hyung, et al.
Publicado: (2014)

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
por: Trojano, Maria, et al.
Publicado: (2021)

Spatial Gradient of Microstructural Changes in Normal-Appearing White Matter in Tracts Affected by White Matter Hyperintensities in Older Age
por: Muñoz Maniega, Susana, et al.
Publicado: (2019)

Subjective discomfort in children receiving 3 T MRI and experienced adults’ perspective on children’s tolerability of 7 T: a cross-sectional questionnaire survey
por: Chou, I-Jun, et al.
Publicado: (2014)

Neurological Disorders Associated With COVID-19 Hospital Admissions: Experience of a Single Tertiary Healthcare Center
por: Dhillon, Permesh Singh, et al.
Publicado: (2021)

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
por: Ramos-Cejudo, Jaime, et al.
Publicado: (2011)

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
por: Gatzonis, Stylianos, et al.
Publicado: (2009)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
por: Cadavid, Diego, et al.
Publicado: (2013)

Impact of Natalizumab Treatment on Fatigue, Mood, and Aspects of Cognition in Relapsing–Remitting Multiple Sclerosis
por: Kunkel, Annett, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nh9uuovk4tri4ifdt1t6ruhur6